Dr. Andrea Apolo from the NCI and the co-Chair of the ASCO GU 2026 scientific program joined the Healthcare Unfiltered EXPRESS to share what she viewed as potentially practice-changing data in bladder cancer. She discussed what she viewed as the top 4 abstracts to be aware of.

Stay up to date on all oncology meetings by subscribing to Healthcare Unfiltered EXPRESS; share with colleagues, and join the conversation.

Dr. Shilpa Gupta of Cleveland Clinic joins Healthcare Unfiltered EXPRESS to share three major abstracts from the ASCO-GU-2026 meeting that could change clinical practice in kidney and prostate cancers. Dr. Gupta brings this data home by explaining their impact on real-world practices. Check these out, subscribe, review, and join the conversation.

Dr. Eric Singhi of the MD Anderson Cancer Center joins Healthcare Unfiltered EXPRESS to describe this newly approved drug, its target, the trial that led to its approval, and how it fits into the treatment armamentarium for lung cancer. Please rate, subscribe, share, and join the conversation.

Arguably, the development and approval of Menin Inhibitors in AML are one of the most important advances in this disease in the past 1-2 years. Dr. Uma Borate joins Healthcare Unfiltered EXPRESS and shares with us everything we must know about this class of drugs: how they are used, their toxicities, and what the future of AML management may look like now that we have Menin inhibitors. Check it out, subscribe, and review.

Dr. Marc Braunstein from NYU Langone joins the Healthcare Unfiltered EXPRESS to describe the recently published BRUIN-313 trial in frontline CLL and its potential impact on the treatment landscape for this disease. Check it out, subscribe, share, and join the conversation.

Dr. Ishwaria Subbiah joined the Healthcare Unfiltered EXPRESS to discuss burnout, a problem physicians and many other healthcare providers face. She offers that AI and technology may bring solutions to reduce this problem and improve satisfaction. Check it out, subscribe, review, share, and join the conversation.

Dr. Sara Tolaney of the Dana-Farber Cancer Institute joined the show to share her insights on the ASCENT-04 trial recently published in NEJM. This is an RCT in triple-negative breast cancer. Sara led this study and as the lead author, she puts its results in context - this is a must-listen episode. Please share, review, and subscribe.

Dr. Ajay Nooka of Emory University and the Winship Cancer Institute joins Healthcare Unfiltered EXPRESS to tell us about CELMoDs in multiple myeloma. What are these agents? How do they work? How do they help patients with myeloma? And what does the future of this disease look like now that we may have CELMoDs for this disease? A must listen, and please share your comments.